The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

In Q4 and full year 2024, Eli Lilly reported revenue of approximately $13.5 billion and $45 billion (up 32% year-over-year), ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

We recently published a list of the 10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a ...

The company (LLY) said orforglipron showed statistically significant results and a safety profile that was consistent with injectable GLP-1 medicines in the Phase 3 trial. The once-daily treatment ...

We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

In contrast, manufactured products are inherently standardized ... medications is a critical tool to meet those goals. Eli Lilly's Cease-and-Desist letter only reinforces and reinvigorates ...